Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Annals of Surgery|September 4, 2015
Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous NeoplasmYoshihiro Miyasaka, Takao Ohtsuka, Koji Tamura, et al.
Annals of Surgery|March 28, 2013
Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtypeNoboru Ideno, Takao Ohtsuka, Hiroshi Kono, et al.
International Journal of Hematology|August 6, 2022
Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemiaMariko Tsuda, Akie Hirata, Shoji Tokunaga, et al.
Cancer Science|January 6, 2011
Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomyRie Amamoto, Mikako Yagi, YooHyun Song, et al.
Pancreas|October 7, 2017
S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal AdenocarcinomaTaketo Matsunaga, Takao Ohtsuka, Koichi Asano, et al.
Respiratory Investigation|November 16, 2019
Characteristics of tobacco-related lung diseases in Fukuoka Prefecture, Japan: A prospective, multi-institutional, observational studySaiko Ogata-Suetsugu, Naoki Hamada, Toru Tsuda, et al.
Cancer Science|October 7, 2016
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210GKohei Shitara, Kimio Yonesaka, Tadamichi Denda, et al.
International Journal of Clinical Oncology|March 20, 2020
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survivalKoji Ando, Yasunori Emi, Nobutomo Miyanari, et al.
Annals of Dermatology|May 12, 2012
A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitisSatoshi Takeuchi, Hidehisa Saeki, Shoji Tokunaga, et al.
International Journal of Clinical Oncology|June 4, 2015
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)Keisuke Miwa, Eiji Oki, Yasunori Emi, et al.
Pageof 12